D. Western Therapeutics Institute DB:6DW 株式レポート D. Western Therapeutics Institute, Inc.
DB:6DW 株式レポート
6DW 株式概要 D.バイオテクノロジー企業であるウェスタン・セラピューティクス・インスティテュート社は、様々な医薬品の発見と開発に注力している。
リスク分析 +1 さらなるリスク
すべてのリスクチェックを見る D. Western Therapeutics Institute, Inc. 競合他社 価格と性能
の歴代最高値、変動、値下がりまとめD. Western Therapeutics Institute 過去の株価 現在の株価 JP¥0.31 52週高値 JP¥0.91 52週安値 JP¥0.27 ベータ 0.74 11ヶ月の変化 -7.10% 3ヶ月変化 -17.80% 1年変化 -63.70% 33年間の変化 -80.74% 5年間の変化 -88.46% IPOからの変化 -90.19%
最新ニュース
D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Aug 27
Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023) Aug 14
New minor risk - Shareholder dilution Jul 23
First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023) May 17
New minor risk - Shareholder dilution May 10
Insufficient new directors May 09 最新情報をもっと見る
D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Aug 27
Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023) Aug 14
New minor risk - Shareholder dilution Jul 23
First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023) May 17
New minor risk - Shareholder dilution May 10
Insufficient new directors May 09
D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024 Feb 28
D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 Feb 14
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024 Feb 11
Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022) Feb 11
D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024 Dec 13
Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022) Nov 13
New minor risk - Share price stability Oct 11
D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023 Aug 27
Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022) Aug 13
D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jun 09
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 May 17
First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022) May 17
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023 Feb 15
Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021) Feb 15
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023 Feb 14
D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023 Dec 06
Insufficient new directors Nov 16
Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021) Nov 12
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 Nov 12
D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Aug 28
Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021) Aug 11 D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc. Jul 20
D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jun 02
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022 May 14
Insufficient new directors Apr 27
D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022 Feb 27
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022 Feb 15
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022 Feb 12
D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021 Mar 03
D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Sep 12
D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm Aug 08
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm Jul 23 株主還元 6DW DE Biotechs DE 市場 7D 0% -2.2% 1.1% 1Y -63.7% -17.1% 13.5%
株主還元を見る
業界別リターン: 6DW過去 1 年間で-17.1 % の収益を上げたGerman Biotechs業界を下回りました。
リターン対市場: 6DWは、過去 1 年間で13.5 % のリターンを上げたGerman市場を下回りました。
価格変動 Is 6DW's price volatile compared to industry and market? 6DW volatility 6DW Average Weekly Movement 6.2% Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
安定した株価: 6DW過去 3 か月間に大きな価格変動はありませんでした。
時間の経過による変動: 6DWの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要 D.バイオテクノロジー企業であるWestern Therapeutics Institute, Inc.は、様々な医薬品の発見と開発に注力している。緑内障・高眼圧症治療薬GLANATECとGLA-ALPHA、眼科治療薬DW-1001、水疱性角膜症の再生医療細胞製品DWR-2206、白内障手術用眼科手術補助剤DW-1002、ILM、ALC、ERM、PVR膜染色を提供している。また、帯状疱疹後の神経障害性疼痛に対するリドカインパッチであるDW-5LBT、第III相臨床試験中のフーチ内皮角膜ジストロフィー治療薬K-321、緑内障／高眼圧症治療薬として第IIb相臨床試験を開始したマルチキナーゼ阻害薬H-1337も開発中である。同社は1999年に設立され、名古屋に本社を置いている。
もっと見る D. Western Therapeutics Institute, Inc. 基礎のまとめ D. Western Therapeutics Institute の収益と売上を時価総額と比較するとどうか。 6DW 基礎統計学 時価総額 €15.77m 収益（TTM） -€6.63m 売上高(TTM ) €2.83m
収益と収入 最新の決算報告書（TTM）に基づく主な収益性統計 6DW 損益計算書（TTM） 収益 JP¥464.00m 売上原価 JP¥40.00m 売上総利益 JP¥424.00m その他の費用 JP¥1.51b 収益 -JP¥1.08b
一株当たり利益（EPS） -28.57 グロス・マージン 91.38% 純利益率 -233.84% 有利子負債／自己資本比率 129.6%
6DW の長期的なパフォーマンスは？
過去の実績と比較を見る
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
